Department of Pharmacoeconomics and Pharmaceutical administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran 1417614411, Iran.
Daru. 2013 Dec 19;21(1):69. doi: 10.1186/2008-2231-21-69.
Supply of medicine as a strategic product in any health system is a top priority. Pharmaceutical companies, a major player of the drug supply chain, are subject to many risks. These risks disrupt the supply of medicine in many ways such as their quantity and quality and their delivery to the right place and customers and at the right time. Therefore risk identification in the supply process of pharmaceutical companies and mitigate them is highly recommended.
In this study it is attempted to investigate pharmaceutical supply chain risks with perspective of manufacturing companies.
Scopus, PubMed, Web of Science bibliographic databases and Google scholar scientific search engines were searched for pharmaceutical supply chain risk management studies with 6 different groups of keywords. All results found by keywords were reviewed and none-relevant articles were excluded by outcome of interests and researcher boundaries of study within 4 steps and through a systematic method.
Nine articles were included in the systematic review and totally 50 main risks based on study outcome of interest extracted which classified in 7 categories. Most of reported risks were related to supply and supplier issues. Organization and strategy issues, financial, logistic, political, market and regulatory issues were in next level of importance.
It was shown that the majority of risks in pharmaceutical supply chain were internal risks due to processes, people and functions mismanagement which could be managed by suitable mitigation strategies.
在任何医疗体系中，药品供应都是重中之重。作为药品供应链的主要参与者之一，制药公司面临着许多风险。这些风险会以多种方式扰乱药品的供应，如数量和质量，以及药品能否按时、按地、按对象送达。因此，建议对制药公司药品供应流程中的风险进行识别并加以缓解。
本研究试图从制药公司的角度调查药品供应链风险。
通过 6 组不同的关键词，在 Scopus、PubMed、Web of Science 书目数据库和 Google Scholar 科学搜索引擎中检索药品供应链风险管理研究。通过 4 个步骤和系统的方法，对关键词检索到的所有结果进行了审查，并根据研究的兴趣结果和研究人员的范围排除了不相关的文章。
系统评价共纳入 9 篇文章，共提取了 50 项基于研究兴趣的主要风险，这些风险分为 7 类。报道的大多数风险与供应和供应商问题有关。组织和战略问题、财务、物流、政治、市场和监管问题的重要性次之。
结果表明，药品供应链中的大多数风险是由于流程、人员和职能管理不善造成的内部风险，可以通过适当的缓解策略来管理。
